About Us | Contact Us |        

The Impact of Earlier Diagnosis and Timelier Treatment of Rheumatoid Arthritis on Patient Outcomes and Healthcare Systems

Title:

The Impact of Earlier Diagnosis and Timelier Treatment of Rheumatoid Arthritis on Patient Outcomes and Healthcare Systems

Topic: Rheumatology
Relevant Terms: Early diagnosis, DMARDs, EULAR, "Don't Delay, Connect Today", World Arthritis Day
Primary Audience: Rheumatologists and rheumatology clinicians
Launch Date: 28-Dec-17
Credits: 0.5 AMA PRA Category 1 Credit
Expiration Date: 27-Dec-18
Curriculum Name: Rheumatoid Arthritis: The Importance of Early Diagnosis and Timely Access to Treatment

Learning Objectives

After completing this activity, the participant will demonstrate the ability to:

  1. Apply the research that defined the benefits associated with early diagnosis and treatment of RA

    Faculty

    Marc D. Cohen, MD
    Emeritus Professor of Medicine
    Mayo Clinic
    Rochester, Minnesota
    Adjunct Professor of Medicine
    Division of Rheumatology
    National Jewish Health
    Denver, Colorado
    Iain B. McInnes, MD, PhD
    Muirhead Chair of Medicine
    Director of the Institute of Infection, Immunity, and Inflammation
    University of Glasgow
    Glasgow, Scotland
    Program Overview
    Delays in diagnoses and early intervention of rheumatic and musculoskeletal diseases, including rheumatoid arthritis (RA), can cause unnecessary disease progression, reduce chances of remission, decrease patients' quality of life, increase co-morbidities, reduce life expectancy, and increase the added cost burden on global healthcare systems. A growing body of evidence supports the concept of a window of opportunity (3 to 6 months after onset of symptoms) during which initiating treatment for RA can relieve symptoms, minimize comorbidities, and reduce the risk for progression and long-term disability. Global medical society guidelines have been revised recently to underscore the importance of earlier diagnosis of RA and to encourage the earlier use of disease modifying antirheumatic drugs (DMARDs) involving a treat-to-target strategy. Clinicians need education about these developments, about the use of established and emerging therapeutic agents for RA, and about strategies for preparing their practices to better manage patients earlier in the course of rheumatic disease.

    Physician Accreditation Statement
    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and Global Academy of Medical Education. Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.
     
    Physician Credit Designation
    Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.
     
    Term of Offering
    This activity was released on December 28, 2017 and is valid for one year. Requests for credit must be made no later than December 27, 2018.
      
    Instructions for Obtaining Credit
    In order to receive credit, participants must complete the online evaluation and post-test at the end of this program. Participants must also score at least a 70% on the post-test. Statements of credit will be issued upon completion of the evaluation and post-test. 

    Fee Information & Refund/Cancellation Policy
    There is no fee for this educational activity.
     
    Disclosure Declarations
    Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
      
    The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
     
    Name of Faculty or Presenter Reported Financial Relationship
    Marc Cohen, MD Has nothing to disclose.
    Iain McInnes, FRCP, PhD, FRSE, FMedSci Consultant: AbbVie; Galapagos Pharma; Lilly; Pfizer. Grant/Research Support: Bristol- Myers Squibb; Janssen; Pfizer; UCB.
     
    The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
     
    Name of Planner or Manager Reported Financial Relationship
    Mike LoPresti Nothing to disclose
    Margaret McLaughlin, PhD Nothing to disclose
    Ron Schaumburg Nothing to disclose
     
    Disclosure of Unlabeled Use
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 
     
    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
     
    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

    Commercial Support Statement

    This activity is supported by an educational grant from Sanofi-Regeneron.
     
    Copyright © 2017 by Global Academy for Medical Education, LLC, Frontline Medical Communications Inc., and its Licensors. All rights reserved. No part of this publication may be reproduced or transmitted in any form, by any means, without prior written permission of the Publisher. Global Academy for Medical Education, LLC, and Postgraduate Institute for Medicine will not assume responsibility for damages, loss, or claims of any kind arising from or related to the information contained in this publication, including any claims related to the products, drugs, or services mentioned herein.
     
    COURSE VIEWING REQUIREMENTS
    Supported Browsers:
    Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
    Google Chrome 28.0+ for Windows, Mac OS, or Linux
    Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
    Safari 6.0+ for Mac OSX 10.7 and above
     
    Supported Phones & Tablets:
    Android 4.0.3 and above
    iPhone/iPad with iOS 6.1 or above.